Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients

References

• Alano CC, Garnier P, Ying W, et al. (2010). NAD + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30:2967–78.
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Thompson CB. (2007). The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13:7271–9.
   PubMed Web of Science ®Google Scholar
• Araujo AP, Catarino R, Ribeiro R, et al. (2012). Epidermal growth factor genetic variation associated with advanced cervical cancer in younger women. Am J Clin Oncol 35:247–50.
   PubMed Web of Science ®Google Scholar
• Balacescu O, Balacescu L, Tudoran O, et al. (2014). Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer 14:246.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Mclendon RE, et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–60.
   PubMed Web of Science ®Google Scholar
• Beneke S, Burkle A. (2007). Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res 35:7456–65.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, et al. (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–65.
   PubMed Web of Science ®Google Scholar
• Catarino R, Matos A, Pinto D, et al. (2005). Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160:49–54.
   PubMedGoogle Scholar
• Catarino R, Pereira D, Breda E, et al. (2008). Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun 370:118–22.
   PubMed Web of Science ®Google Scholar
• Chalmers A, Johnston P, Woodcock M, et al. (2004). PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58:410–19.
   PubMed Web of Science ®Google Scholar
• Chevanne M, Calia C, Zampieri M, et al. (2007). Oxidative DNA damage repair and parp 1 and parp 2 expression in Epstein-Barr virus-immortalized B lymphocyte cells from young subjects, old subjects, and centenarians. Rejuvenation Res 10:191–204.
   PubMed Web of Science ®Google Scholar
• Chung HH, Kim MK, Kim JW, et al. (2006). XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 103:1031–7.
   PubMed Web of Science ®Google Scholar
• Coelho A, Matos A, Catarino R, et al. (2005). Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 96:760–4.
   PubMed Web of Science ®Google Scholar
• Cottet F, Blanche H, Verasdonck P, et al. (2000). New polymorphisms in the human poly(ADP-ribose) polymerase-1 coding sequence: lack of association with longevity or with increased cellular poly(ADP-ribosyl)ation capacity. J Mol Med (Berl) 78:431–40.
   PubMed Web of Science ®Google Scholar
• Craveiro R, Bravo I, Catarino R, et al. (2012). The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer. DNA Cell Biol 31:224–9.
   PubMed Web of Science ®Google Scholar
• Craveiro R, Costa S, Pinto D, et al. (2004). TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet 150:116–21.
   PubMedGoogle Scholar
• Davis JD, Lin SY. (2011). DNA damage and breast cancer. World J Clin Oncol 2:329–38.
   PubMedGoogle Scholar
• de las Penas R, Sanchez-Ronco M, Spanish Lung Cancer Group, et al. (2006). Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668–75.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Retrospective International Survey and HPV Time Trends Study Group, et al. (2010). Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–56.
   PubMed Web of Science ®Google Scholar
• Dianov GL, Hubscher U. (2013). Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res 41:3483–90.
   PubMed Web of Science ®Google Scholar
• Eustermann S, Videler H, Yang JC, et al. (2011). The DNA-binding domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its second zinc finger. J Mol Biol 407:149–70.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–86.
   PubMed Web of Science ®Google Scholar
• Fouquerel E, Sobol RW. (2014). ARTD1 (PARP1) activation and NAD(+) in DNA repair and cell death. DNA Repair (Amst) 23:27–32.
   PubMed Web of Science ®Google Scholar
• Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. (2008). Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem 16:10121–8.
   PubMed Web of Science ®Google Scholar
• Hao B, Wang H, Zhou K, et al. (2004). Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64:4378–84.
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA, Gu J, Wu X. (2009). Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5:745–55.
   PubMed Web of Science ®Google Scholar
• Kim MY, Zhang T, Kraus WL. (2005). Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD + into a nuclear signal. Genes Dev 19:1951–67.
   PubMed Web of Science ®Google Scholar
• Kristensen GB, Abeler VM, Risberg B, et al. (1999). Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 74:245–51.
   PubMed Web of Science ®Google Scholar
• Lockett KL, Hall MC, Xu J, et al. (2004). The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64:6344–8.
   PubMed Web of Science ®Google Scholar
• Masutani M, Nakagama H, Sugimura T. (2003). Poly(ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer 38:339–48.
   PubMed Web of Science ®Google Scholar
• Medeiros R, Prazeres H, Pinto D, et al. (2005). Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. Eur J Cancer Prev 14:467–71.
   PubMed Web of Science ®Google Scholar
• Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. (2002). Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 11:1054–64.
   PubMed Web of Science ®Google Scholar
• Moore DH. (2006). Cervical cancer. Obstet Gynecol 107:1152–61.
   PubMed Web of Science ®Google Scholar
• Nguewa PA, Fuertes MA, Alonso C, Perez JM. (2003). Pharmacological modulation of Poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy. Mol Pharmacol 64:1007–14.
   PubMed Web of Science ®Google Scholar
• Nguewa PA, Fuertes MA, Valladares B, et al. (2005). Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 88:143–72.
   PubMed Web of Science ®Google Scholar
• Nogueira A, Assis J, Catarino R, Medeiros R. (2013). DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. Pharmacogenomics 14:689–700.
   PubMed Web of Science ®Google Scholar
• Nogueira A, Catarino R, Coelho A, et al. (2010). Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother Pharmacol 66:501–6.
   PubMed Web of Science ®Google Scholar
• Nogueira A, Catarino R, Faustino I, et al. (2012). Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy. Gene 504:279–83.
   PubMed Web of Science ®Google Scholar
• Santos AM, Sousa H, Catarino R, et al. (2005). TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159:143–7.
   PubMedGoogle Scholar
• Santos AM, Sousa H, Pinto D, et al. (2006). Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 42:958–63.
   PubMed Web of Science ®Google Scholar
• Shen SN, Wang LF, Jia YF, et al. (2013). Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 8:69.
   PubMed Web of Science ®Google Scholar
• Shi TY, Yang G, Tu XY, et al. (2012). RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS One 7:e50461.
   PubMed Web of Science ®Google Scholar
• Shibata A, Kamada N, Masumura K, et al. (2005). Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 24:1328–37.
   PubMed Web of Science ®Google Scholar
• Silva IH, Nogueira-Silva C, Figueiredo T, et al. (2013). The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer. Gene 512:247–50.
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, et al. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–32.
   PubMed Web of Science ®Google Scholar
• Tong WM, Cortes U, Wang ZQ. (2001). Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 1552:27–37.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19.
   PubMed Web of Science ®Google Scholar
• Wang LE, Yin M, Dong Q, et al. (2011). DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 29:4121–8.
   PubMed Web of Science ®Google Scholar
• Wei Q, Frazier ML, Levin B. (2000). DNA repair: a double-edged sword. J Natl Cancer Inst 92:440–1.
   PubMedGoogle Scholar
• Yelamos J, Farres J, Llacuna L, et al. (2011). PARP-1 and PARP-2: new players in tumour development. Am J Cancer Res 1:328–46.
   PubMed Web of Science ®Google Scholar
• Yu SW, Andrabi SA, Wang H, et al. (2006). Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A 103:18314–19.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Y, Li X, et al. (2009). PARP-1 Val762Ala polymorphism, CagA + H. pylori infection and risk for gastric cancer in Han Chinese population. Mol Biol Rep 36:1461–7.
   PubMed Web of Science ®Google Scholar
• Zhang X, Miao X, Liang G, et al. (2005). Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65:722–6.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang C, Narayani N, et al. (2007). Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells. Cancer Lett 255:127–34.
   PubMed Web of Science ®Google Scholar
• Zhu G, Chang P, Lippard SJ. (2010). Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry 49:6177–83.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. (1989). Host cell regulation of HPV transforming gene expression. Int Symp Princess Takamatsu Cancer Res Fund 20:207–19.
   PubMedGoogle Scholar